cancer clinic trial elig criteria patient organ dysfunct prior concurr malign guidanc industri us depart health human servic food drug administr oncolog center excel center drug evalu research cder center biolog evalu research cber juli 2020 clinicalmed cancer clinic trial elig criteria patient organ dysfunct prior concurr malign guidanc industri addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10001 new hampshir ave hillandal bldg 4th floor silver spring md 20993 0002 phone 8555433784 301 7963400 fax 3014316353 email druginfofdahhsgov httpswwwfdagovdrugsguid complianc regulatori informationguid drug andor offic commun outreach develop center bi olog evalu research food drug administr 10903 new hampshir ave bldg 7 1 rm 3128 silver spring md 20993 0002 phone 8008354709 240 4028010 email ocodfdahhsgov httpswwwfdagovvaccin blood biologicsguid complianc regulatori inform biologicsbiolog guidanc us depart health human servic food drug administr oncolog center excel center drug evalu research cder center biolog evalu research cber juli 2020 clinicalmed contain nonbind recommend tabl content introduct 1 ii background 2 iii recommend 3 patient organ dysfunct 3 1 renal function recommend 3 2 cardiac function recommend 4 3 hepat function recommend 5 b patient prior con current malign 5 contain nonbind recommend 1 cancer clinic trial elig criteria patient organ dysfunct prior concurr malign guidanc industry1 guidanc repres current think food drug administr fda agenc topic establish right person bind fda public use altern approach satisfi requir applic statut regul discuss altern approach contact fda offic respons guidanc list titl page introduct guidanc one seri guidanc provid recommend regard elig criteria clinic trial drug biolog products2 regul cder cber treatment cancer 3 specif guid anc includ recommend regard inclus patient organ dysfunct prior concurr malign guidanc intend assist stakehold includ sponsor institut review board respons developm ent oversight clinic trial clinic trial elig criteria inclus exclus essenti compon trial defin characterist studi popul variabl investig drug trial object elig criteria develop take consider mechan action drug target diseas patient popul anticip safeti investig drug avail adequ safe ty data abil recruit trial particip patient popul meet object clinic trial howev elig criteria becom commonli accept ti use templat across trial without clear sc ientif clinic rational unnecessarili restrict elig criteria may slow patient accrual limit patient access clinic trial 1 guidanc prepar oncolog center excel center drug evalu research cder center biolog evalu research cber food drug administr 2 purpos guidanc refer drug drug biolog product includ drug approv section 505 feder food drug cosmet act 21 usc 355 biolog product licens section 351 public health servic act 42 usc 262 3 topic three guidanc relat elig criteria patient human immunodefici viru hepat b viru hepat c viru infect pat ient brain metastas regard minimum age consider inclus pedi atric patient contain nonbind recommend 2 lead trial result fulli repres treatment effect patient popul ultim use drug45 broaden cancer trial elig criteria maxim generaliz trial result abil understand therapi benefit risk profil cross patient popul like use drug clinic practic consid avoid jeopard patient safeti trial design methodolog approach import consider enrol broader popul ad dress elsewhere67 address guidanc consider specif enrol patient organ dysfunct prior concurr malign gener fda guidanc document establish legal enforc abl respons instead guidanc describ agenc current think topic view recommend unless specif regulatori statutori requir cite use word agenc guidanc mean hat someth suggest recommend requir ii background patient organ dysfunct often exclud clinic trial regardless knowledg metabol pathway excretori rout investig drug lifespan gener popul increas thu includ increas number patient comorbid renal diseas cardiac diseas hepat dysfunct addit lifespan gener popul increa es greater number patient anticip prior concurr malig nanci exclud individu cancer clinic trial major organ dysfunct previou concurr cancer trial recruit may favor younger patient may fulli repres popul drug indic design cancer clinic trial includ patient organ dysfunct prior concurr malign includ inform label promot safe effect use product across broad er patient popul like use drug clinic practic 4 beaver ja ison g pazdur r 2017 reevalu elig criteria balanc patient protect particip oncolog trial nejm 3761504 1505 5 kim e bruinoog robert et al 2017 broaden elig criteria make clinic trial repres american societi clinic oncolog friend cancer research joint research statement jco 3533 3737 3744 6 see draft guidanc industri enhanc divers clinic trial popul elig criteria enrol practic trial design june 2019 final guidanc repres fda current think th topic updat guidanc period recent version guidanc check fda guidanc web page httpswwwfdagovregulatori informationsearch fdaguid document 7 jin pazdur r sridhara r 2017 evalu elig criteria oncolog clinic trial analysi investig new drug applic 2015 jco 3533 3745 3752 contain nonbind recommend 3 iii recommend thought consider given potenti inclus patient organ dysfunct prior concurr malign cancer clinic trial follow recommend elig criteria patient organ dysfunct cancer clinic trial focu renal function cardiac function hepat function guidanc also includ recommend elig criteria patient cancer prior concurr malign patient organ dysfunct pharmacokinet pk major rout elimin human well understood reason enrol patient rel preserv organ function primarili renal hepat cancer clinic trial data toxic includ nonclin clinic toxic pk pharmacodynam pd becom avail drug develop protocol revis includ patient compromis organ function safe paramet regard dosag adjust determined8 1 renal function recommend elig criteria base contemporari wide accept clinic applic equat estim glomerular filtrat rate measur glomerular filtrat rate rather absolut serum creatinin concentr equ ation use particular patient popul remain consist throughout investig drug develop process sponsor provid adequ justif inclusionexclus patient variou degre renal impairm nt base stage product develop safeti profil product understand effect renal impair elimin drug safeti studi procedur patient renal impair patient renal impair includ trial investig drug avail nonclin clinic data indic inclus patient renal impair would place patient unreason risk andor adequ st ep taken mitig potenti risk expect system exposur increas patient renal dysfunct inclus patient may facilit prospect dose adjust produc similar system exposur seen patient rel preserv kidney function9 8 lichtman harvey r smit et al 2017 modern ize clinic trial elig criteria recommend american societi clinic oncolog friend cancer research organ dysfunct prior concurr malign comorbid work group jco 3533 3753 3759 9 public worksh op evalu inclus exclus criteria clinic trial workshop report juli 2018 workshop date april 16 2018 avail httpswwwfd anewscomextresourcesfiles201808 2218 fdasummarypdf1534970149 access june 23 2020 contain nonbind recommend 4 sponsor address need time studi evalu effect dialysi drug clearanc need dosag adjust patient dialysi adequ represent patient vari degre renal impair well data suffici adequ describ impact renal impair pk drug popul pharmacokinet poppk analys data phase 2 phase 3 clinic trial may suffici character impact renal function 2 cardiac function recommend inclus patient cardiovascular dysfunct may possibl avail nonclin clinic data includ pk pd data indic inclus patient expos unreason risk patient signific clinic cardiac abnorm eg clinic heart failur unstabl angina exclud especi earli phase studi inclus criteria requir investig assess potenti particip risk heart failur valid clinic classif system eg new york heart associ function classif eject fraction e f measur ef measur either echocardiographi multig acquisit scan accept deter mine cardiac ef elig criteria purpos qtc prolong 10 sponsor assess effect drug qtc earli clinic develop sponsor determin whether maximum qtc interv necessari clinic trial elig criteri base whether specif known risk qtc prolong either non clinic eg herg clinic trial data 10 see ich guidanc industri e14 clinic evalu qtqtc interv prolong proarrhythm potenti non antiarrhythm drug octob 20 05 ich guidanc industri e14 clinic evalu qtqtc inter val prolong proarrhythm potenti non antiarrhythm drug question answer r3 june 2017 addit inform regard qtc prolong contain nonbind recommend 5 3 hepat function recommend unlik organ system liver biochem test provid suffici evid adequ liver drug metabol function e stimat hepat function incorpor clinic variabl well function laboratori valu child pugh model end stage liver diseas score system 1112 adopt marker hepat metabol dedic pk studi hepat metabol may also influenc cancer inflamm even set normal score gaug hepat drug transf ormat capac pre exist liver diseas well epidemiolog genet environment histor variabl eg chronic alcohol use past histori advers drug reaction ascertain impair hepat blood flow part icular portal hypertens ev ident critic assess liver metabol drug inclus patient sever hepat impair discuss fda patient mild moder hepat impairment13 defin equival nation cancer institut common terminolog criteria advers event nci ctc ae grade 1 toxic well aspart transaminas ast alanin transaminas alt elev defin grade 3 nci ctcae 5 20 x uln upper limit normal may asymptomat abl toler dose equival patient normal hepat function inclus patient mild moder hepat impair may appropri avail nonclin clinic data includ pk pd data indic inclus patient present unreason risk patient b patient prior concurr malign patient prior malign differ tumor type patient concurr malignanc i differ tumor type refer prior conc urrent malign guidanc whose natur histori treatment potenti interfer safeti efficaci assess investig drug gener elig enrol clinic trial exampl initi dose find preliminari activ estim proof ofconcept studi patient histori prior concurr malign exclud 11 see guidanc industri pharmacokinet patient impair hepat function studi design data analysi impact dose label may 2003 12 see protoco l templat organ dysfunct studi updat februari 5 2020 nci criteria avail httpsctepcancergovprotocoldevelopmenttemplatesappl htm access june 23 2020 13 talal ah venuto cs youni 2017 assess hepat impair implic pharmacokinet substanc use treatment clin pharmacol drug dev 6 206 212